In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019.

Temesgen, Zelalem; Kenderian, Saad S; Badley, Andrew D

Temesgen, Zelalem; Kenderian, Saad S; Badley, Andrew D.

Temesgen Z; Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
Kenderian SS; Division of Hematology, T Cell Engineering, Mayo Clinic, Rochester, MN.
Badley AD; Division of Infectious Diseases, Department of Molecular Medicine, Mayo Clinic, Rochester, MN.

Mayo Clin Proc ; 96(3): 817-818, 2021 03.

Article in English | MEDLINE | ID: covidwho-1019365

Subject(s)

COVID-19; Antibodies, Monoclonal, Humanized; Cohort Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: Mayo Clin Proc Year: 2021 Document Type: Article Affiliation country: J.mayocp.2020.12.029

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google